Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MLAB and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MLAB and 80,000+ other tickers.
See exactly how MLAB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MLAB and 80,000+ other tickers.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical…
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) and ImmunoPrecise Antibodies (OTCMKTS:IPATF - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations. Earnings and Valuation This table compares Mesa Laboratories
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced it will release financial results for its first fiscal quarter (“1Q27”) ended June 30, 2026 following market close on Monday, August 10, 2026. The Company will also hold its first earnings conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.